Recent investigations have focused on the intersection of GLP-1|GIP|GCGR stimulant therapies and dopamine communication. While GIP agonists are widely employed for treating type 2 T2DM, their potential impacts on reward circuits, specifically influenced by dopaminergic networks, are attracting considerable interest. This report details a summary as